Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug-drug interactions for Vericiguat

• Main Authors: Sebastian Frechen (Author), Ibrahim Ince (Author), André Dallmann (Author), Michael Gerisch (Author), Natalia A. Jungmann (Author), Corina Becker (Author), Maximilian Lobmeyer (Author), Maria E. Trujillo (Author), Shiyao Xu (Author), Rolf Burghaus (Author), Michaela Meyer (Author)
• Format: Book
• Published: Wiley, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Vericiguat (Verquvo; US: Merck, other countries: Bayer) is a novel drug for the treatment of chronic heart failure. Preclinical studies have demonstrated that the primary route of metabolism for vericiguat is glucuronidation, mainly catalyzed by uridine diphosphate‐glucuronosyltransferase (...